U.S. Markets closed

Novartis’s Innovative Medicines Business in Q2 2018

Mike Benson
Novartis’s Innovative Medicines Business in Q2 2018

As we’ve already seen, Novartis’s (NVS) Innovative Medicines business includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology. Innovative Medicines contributed ~67.4% of Novartis’s total revenues in Q2 2018, a 10% growth YoY (year-over-year) to $8.9 billion.